Gravity Analytica

MannKind to Present at 2024 UBS Healthcare Conference

MNKD 11.05.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:2024 UBS Healthcare Conference

Full Press Release SEC Filings Our MNKD Tweets

About Gravity Analytica

Recent Filings

01.06.2025 - 8-K Current report

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.,Nov. 05, 2024(GLOBE NEWSWIRE) --MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference inRancho Palos Verdes, Calif.

The fireside chat will take place on Tuesday, November 12, at 10:15 a.m. Pacific Time. A link to the live audio webcast of the session will be available on MannKind Corporation’s website at:https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available on the website for approximately 30 days following the conference.

AboutMannKindMannKind Corporation(Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visitmannkindcorp.comto learn more, and follow us onLinkedIn,Facebook,XorInstagram.

This press release was published by a CLEAR® Verified individual.

For MannKind:Investor RelationsAna Kapor(818) 661-5000Email: ir@mnkd.comMedia RelationsChristie Iacangelo(818) 292-3500Email: media@mnkd.com

Source: MannKind

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com